Yoshida Shigetoshi, Iwata Takekazu, Chiyo Masako, Smith Gerald N, Foresman Brian H, Mickler Elizabeth A, Heidler Kathleen M, Cummings Oscar W, Fujisawa Takehiko, Brand David D, Baker Andrew, Wilkes David S
Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Transplantation. 2007 Mar 27;83(6):799-808. doi: 10.1097/01.tp.0000258600.05531.5d.
Upregulation of matrix metalloproteinases (MMPs) has been associated with chronic lung allograft rejection known as bronchiolitis obliterans syndrome. It has been suggested that MMP inhibition could prevent the rejection response. However, the effect of MMP inhibition on lung allograft rejection has not been reported.
Utilizing a rat model of lung transplantation, tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) were overexpressed by gene therapy in F344 rat lung allografts prior to transplantation into WKY recipient rats. Separately, WKY rats that received F344 lung allografts were treated systemically with COL-3, a global MMP inhibitor.
TIMP-1 and TIMP-2 had differential effects on delayed type hypersensitivity (DTH) responses to donor antigens and type V collagen, an autoantigen involved in the rejection response. Neither TIMP-1 or TIMP-2 affected the onset of rejection pathology. COL-3 suppressed DTH responses to donor antigens and type V collagen, abrogated local production of tumor necrosis factor-alpha, and interleukin-1beta. Although it did not prevent rejection pathology, COL-3 (30 mg/kg) induced intragraft B cell hyperplasia suggestive of posttransplant proliferative disorder (PTLD).
These data identify a complex role for MMPs and TIMPs in the immunopathogenesis of lung allograft rejection, and indicate their effects are not limited to matrix remodeling.
基质金属蛋白酶(MMPs)的上调与称为闭塞性细支气管炎综合征的慢性肺移植排斥反应相关。有人提出MMP抑制可预防排斥反应。然而,MMP抑制对肺移植排斥反应的影响尚未见报道。
利用大鼠肺移植模型,在将F344大鼠肺同种异体移植物移植到WKY受体大鼠之前,通过基因治疗使金属蛋白酶组织抑制剂(TIMP-1和TIMP-2)过表达。另外,接受F344肺同种异体移植物的WKY大鼠用COL-3(一种全身性MMP抑制剂)进行全身治疗。
TIMP-1和TIMP-2对针对供体抗原和V型胶原(一种参与排斥反应的自身抗原)的迟发型超敏反应(DTH)有不同影响。TIMP-1和TIMP-2均未影响排斥病理的发生。COL-3抑制对供体抗原和V型胶原的DTH反应,消除肿瘤坏死因子-α和白细胞介素-1β的局部产生。虽然它没有预防排斥病理,但COL-3(30mg/kg)诱导移植物内B细胞增生,提示移植后增殖性疾病(PTLD)。
这些数据确定了MMPs和TIMPs在肺移植排斥反应免疫发病机制中的复杂作用,并表明它们的作用不限于基质重塑。